Skip to content

Building payer considerations into organisational DNA from discovery to commercialisation


The client

Senior Executive Team of a leading biopharma

Services delivered

Insocius catalysis™


Payer considerations,
real world evidence,
R&D, commercial,
operating model,
country engagement


The Senior Executive Team of a leading biopharma was looking to accelerate the integration of a new payer and RWE function. This would be responsible for building payer considerations into drug development from Phase II onwards and generating observational data in support of all Phase II, III and LCM assets.

The solution


Insocius supported a two-year programme to embed payer considerations into the R&D and commercial operating model. The internal engagement campaign enabled all functions to appreciate the emerging role of payers as decision-makers and the need for evidence beyond traditional RCTs.

Country-focused roll out: roll out of a country-focused payer excellence capability programme.

  • Establishment of the Head of Payer and RWE as a leader in the industry.
  • Stakeholder mapping and identification of high-impact channels through which to engage. Development of core support materials (speaker notes, slides, briefing notes).

Embed new function and operating model: change support for the establishment of the new payer and RWE function and operating model including the definition of ‘enterprise offer’ and activation of employees as advocates.


The results

Content Image
85% awareness of payer needs in key functions at global, regional and key country levels
Content Image
Increase in demand for RWE studies by function within one year of launch (in line with capability build)
Content Image
Payer evidence plan built for all phase III assets within first 12 months

Delivering impact with agility and pace

We’re proud of the projects we’ve worked on. Read more from our collection of case studies to discover how we’ve helped shape our clients’ futures.